New York Life Investment Management LLC Grows Position in United Therapeutics Co. (NASDAQ:UTHR)

New York Life Investment Management LLC grew its stake in United Therapeutics Co. (NASDAQ:UTHRFree Report) by 90.8% in the third quarter, Holdings Channel reports. The fund owned 5,406 shares of the biotechnology company’s stock after purchasing an additional 2,573 shares during the period. New York Life Investment Management LLC’s holdings in United Therapeutics were worth $1,221,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of UTHR. Hazlett Burt & Watson Inc. grew its holdings in shares of United Therapeutics by 24.0% during the 2nd quarter. Hazlett Burt & Watson Inc. now owns 248 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 48 shares during the period. KBC Group NV grew its holdings in shares of United Therapeutics by 6.2% during the 2nd quarter. KBC Group NV now owns 820 shares of the biotechnology company’s stock worth $181,000 after purchasing an additional 48 shares during the period. TD Asset Management Inc grew its holdings in shares of United Therapeutics by 1.5% during the 2nd quarter. TD Asset Management Inc now owns 3,362 shares of the biotechnology company’s stock worth $742,000 after purchasing an additional 49 shares during the period. Alaska Permanent Fund Corp boosted its holdings in United Therapeutics by 1.7% during the 3rd quarter. Alaska Permanent Fund Corp now owns 3,330 shares of the biotechnology company’s stock valued at $752,000 after acquiring an additional 57 shares during the period. Finally, Federated Hermes Inc. boosted its holdings in United Therapeutics by 0.5% during the 1st quarter. Federated Hermes Inc. now owns 13,603 shares of the biotechnology company’s stock valued at $2,441,000 after acquiring an additional 61 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $238.89, for a total transaction of $1,433,340.00. Following the completion of the sale, the executive vice president now owns 36,599 shares of the company’s stock, valued at $8,743,135.11. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $238.89, for a total value of $1,433,340.00. Following the completion of the sale, the executive vice president now owns 36,599 shares of the company’s stock, valued at $8,743,135.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Nilda Mesa sold 605 shares of the company’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $244.90, for a total value of $148,164.50. Following the completion of the sale, the director now directly owns 5,698 shares of the company’s stock, valued at approximately $1,395,440.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,605 shares of company stock valued at $7,676,365. Company insiders own 12.50% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Morgan Stanley lowered their target price on United Therapeutics from $318.00 to $314.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. JPMorgan Chase & Co. increased their price target on United Therapeutics from $290.00 to $294.00 and gave the company an “overweight” rating in a research report on Thursday, November 2nd. Wedbush reaffirmed an “outperform” rating and issued a $308.00 price target (up previously from $307.00) on shares of United Therapeutics in a research report on Thursday, November 2nd. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 1st. Finally, SVB Leerink started coverage on United Therapeutics in a research report on Monday. They issued an “outperform” rating and a $330.00 price target on the stock. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, United Therapeutics presently has an average rating of “Buy” and a consensus price target of $301.44.

Check Out Our Latest Stock Report on United Therapeutics

United Therapeutics Stock Performance

United Therapeutics stock opened at $214.95 on Wednesday. The firm has a market capitalization of $10.10 billion, a P/E ratio of 11.84 and a beta of 0.52. The stock has a fifty day moving average price of $227.03 and a 200 day moving average price of $228.45. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $261.54. The company has a current ratio of 4.65, a quick ratio of 4.51 and a debt-to-equity ratio of 0.09.

About United Therapeutics

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Articles

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHRFree Report).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.